Alkermes plc (ALKS)
| Market Cap | 4.71B |
| Revenue (ttm) | 1.13B |
| Net Income (ttm) | -129.14M |
| Shares Out | 164.31M |
| EPS (ttm) | -0.78 |
| PE Ratio | n/a |
| Forward PE | 588.24 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,169,340 |
| Open | 28.79 |
| Previous Close | 28.79 |
| Day's Range | 28.53 - 29.04 |
| 52-Week Range | 21.75 - 32.79 |
| Beta | 0.56 |
| Analysts | Buy |
| Price Target | 32.03 (+11.84%) |
| Earnings Date | Feb 15, 2023 |
About ALKS
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia a... [Read more]
Financial Performance
In 2021, Alkermes's revenue was $1.17 billion, an increase of 13.00% compared to the previous year's $1.04 billion. Losses were -$48.17 million, -56.55% less than in 2020.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for ALKS stock is "Buy." The 12-month stock price forecast is $32.03, which is an increase of 11.84% from the latest price.
News
Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
— Designation Marks Entry Point into MHRA's Innovative Licensing and Access Pathway (ILAP) Program in the UK — DUBLIN , Jan. 17, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that...
Alkermes to Present at the 41st Annual J.P. Morgan Healthcare Conference
DUBLIN , Dec. 28, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 41st Annual J.P. ...
Alkermes (ALKS) Up 4.4% Since Last Earnings Report: Can It Continue?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
Alkermes to Participate in the BofA Securities 2022 Biotech SMID Cap Conference
DUBLIN , Nov. 30, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat as part of the BofA Securities 2022 Biotech SMID Cap Conference o...
How Alkermes (ALKS) Stock Stands Out in a Strong Industry
Alkermes (ALKS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Alkermes to Participate in the 5th Annual Evercore ISI HealthCONx Conference
DUBLIN , Nov. 22, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday,...
Alkermes to Participate in the Stifel Healthcare Conference
DUBLIN , Nov. 8, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Tuesday, Nov. 15, 2022...
Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss
Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the same. The company tightens total revenue guidance for 2022.
Alkermes (ALKS) Q3 Earnings Match Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of 0% and 8.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Alkermes plc Reports Third Quarter 2022 Financial Results
— Third Quarter Revenues of $252.4 Million Reflect Strong Year-Over-Year Growth of Proprietary Commercial Product Portfolio — — GAAP Loss per Share of $0.39 and Non-GAAP Earnings per Share of $0. 02...
Alkermes plc Announces Intent to Separate Oncology Business
— Alkermes to Focus on Profitable Growth of Pure-Play, Commercial-Stage Neuroscience Business — — Separation Expected to Unlock Value Through Sharpened Strategic Focus, Simplified Capital Allocation D...
Alkermes Announces Recipients of 2022 Alkermes Inspiration Grants® Program
– 6th Installment of Competitive Grants Program Awards Funding to Nine Innovative Programs Focused on People Living with Addiction, Serious Mental Illness or Cancer – DUBLIN , Oct. 27, 2022 /PRNewswi...
Alkermes to Report Third Quarter Financial Results on Nov. 2, 2022
DUBLIN , Oct. 26, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m.
Acorda Therapeutics Announces $16.5M Award and Royalty/Supply Relief in AMPYRA® Arbitration Case
PEARL RIVER, N.Y.
Alkermes, Allakos See Activist Action
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.
Alkermes Announces Launch of 5th Annual Alkermes Pathways Research Awards® Program
-- Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project -- -- Application Period Open Until Nov. 30, 2022 -- DUBLIN , Sept. 28, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq:...
Alkermes Showcases Research from Psychiatry Portfolio at Psych Congress
̶ Clinical, Epidemiology and Health Economics and Outcomes Research Shared at Key Psychiatry Conference ̶ DUBLIN , Sept. 20, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the pres...
GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance
GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.
Are Medical Stocks Lagging Alkermes (ALKS) This Year?
Here is how Alkermes (ALKS) and Elevance Health (ELV) have performed compared to their sector so far this year.
Alkermes (ALKS) Could Find Support Soon, Here's Why You Should Buy the Stock Now
Alkermes (ALKS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall ...
3 Companies Growing Revenue Fast
S&P 500 stocks have posted average growth of 6.54% in annual total revenue from 2017 to 2021. The benchmark index for the U.S. stock market closed at 4,122.47 on Tuesday, up nearly 70% over the past f...
Alkermes (ALKS) Loses 16.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Alkermes (ALKS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates ...
Alkermes' (ALKS) Earnings & Revenues Surpass Estimates in Q2
Alkermes (ALKS) beat estimates for both earnings and sales in the second quarter of 2022. The company narrows sales guidance for Vivitrol and Aristada.
Alkermes (ALKS) Q2 Earnings and Revenues Top Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of 50% and 1.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Alkermes plc Reports Second Quarter 2022 Financial Results
— Second Quarter Revenues of $276.2 Million Reflect Strong Growth in Proprietary Net Sales — — GAAP Loss per Share of $0.18 and Non-GAAP Earnings per Share of $0. 06 — — Raises Financial Expe...